Nanograb
Nanograb, based in San Francisco and London, is a healthcare company specializing in drug discovery and delivery using AI to create targeted treatments. The team of three scientists, with extensive experience in antibody design, participated in Y Combinator's S23 batch and launched in 2023.
Company Overview
Nanograb is a healthcare company specializing in drug discovery and delivery. The company launched in 2023 and participated in Y Combinator's S23 batch. With operations based in San Francisco, CA, USA, and London, England, Nanograb aims to redefine healthcare by leveraging AI to generate optimal combinations of binders for treating various diseases.
Innovative Drug Delivery Solutions
Nanograb's core product is a sophisticated platform that utilizes multivalent nanoparticles for next-generation targeting capabilities. This technology allows for drugs to be specifically directed to precise areas of the body, potentially increasing the efficacy and reducing side effects. The use of AI to optimize binder combinations further sets Nanograb apart in the field of drug discovery and delivery.
Team and Expertise
The Nanograb team is composed of three scientists with extensive experience in the scientific community. They have worked together for years, focusing on enhancing antibody design and bringing innovative scientific advancements to practical applications. Their deep understanding of drug discovery, coupled with a fresh perspective, aims to translate groundbreaking science into effective healthcare products.
Global Reach
Nanograb operates in key regions such as the United States of America, the United Kingdom, America, Canada, and Europe. This broad geographical presence underscores the company's ability to impact global healthcare markets, facilitating the spread of their cutting-edge drug delivery technologies across various territories.
Y Combinator Experience
Nanograb was a participant in the prestigious Y Combinator S23 batch. This experience has equipped the company with essential insights, mentorship, and networking opportunities, further aiding in the development and refinement of their innovative drug targeting solutions.
